Zai Lab Wins FDA Fast Track for DLL3-Targeting Zocilurtatug Pelitecan in epNECs
ZLAB•Zai Lab’s DLL3-targeting antibody-drug conjugate Zocilurtatug Pelitecan has secured U.S. FDA Fast Track designation for treating extrapulmonary neuroendocrine carcinomas. The designation aims to expedite development and review processes, potentially accelerating Zai Lab’s clinical timeline for this epNEC therapy.
1. Fast Track Designation
Zai Lab announced that the FDA has granted Fast Track status to Zocilurtatug Pelitecan for the treatment of extrapulmonary neuroendocrine carcinomas. This designation is designed to facilitate accelerated development and review, potentially allowing more frequent communications with the FDA and eligibility for priority review.
2. Zocilurtatug Pelitecan Mechanism
Zocilurtatug Pelitecan is an antibody-drug conjugate targeting DLL3, a protein overexpressed in neuroendocrine carcinomas including epNECs. The ADC delivers a cytotoxic payload directly to DLL3-positive tumor cells, aiming to improve efficacy and reduce systemic toxicity.
3. Next Steps and Timeline
Zai Lab plans to advance Zocilurtatug Pelitecan into late-stage clinical trials, with enrollment expected to begin in the second half of 2026. Key upcoming milestones include dose escalation results and submission for priority review upon successful Phase II outcomes.
